Bedrijfsoverzicht
Pulsenmore Ltd. is a healthcare entity focused on the development and provision of self-scan ultrasound devices designed to facilitate remote clinical diagnosis and screening operations primarily within Israel and Europe. The company operates within the broader Healthcare sector, specifically targeting the Medical Devices industry, which implies a specialization in manufacturing or supplying equipment that aids in non-invasive patient assessment and diagnostic imaging. As a relatively small-cap issuer, Pulsenmore Ltd. maintains a market capitalization of $23.35M and employs a workforce of 71 individuals to support its operations. The combination of a $23.35M market cap and N/A annual revenue figures indicates that the company is in a high-growth or early-commercialization phase, where valuation is driven by future potential and technological innovation rather than established historical earnings or massive scale. This positioning suggests the company is prioritizing market penetration and product adoption over immediate profitability, a common characteristic for firms introducing specialized medical technologies into competitive markets.
Financiële gezondheid
The company reports N/A for trailing twelve-month revenue and N/A for net income, while reporting an EBITDA of $-10,328,000, which reveals a significant gap between operational revenue generation and bottom-line profitability due to substantial costs or investments not fully covered by current sales. Despite the negative net income and EBITDA, Pulsenmore Ltd. reports a free cash flow of $7.69M, indicating that the company generates sufficient cash from operations to cover capital expenditures and other cash obligations, thereby maintaining a degree of financial flexibility despite accounting losses. The gross margin stands at 84.2%, suggesting a highly efficient cost of goods sold structure typical of high-tech medical device manufacturers, yet the operating margin is 0.0% and the profit margin is -39.6%, highlighting that high production efficiency does not yet translate to overall profitability due to significant operating expenses. The balance sheet shows N/A for cash and N/A for debt, with a debt-to-equity ratio of 1.88, indicating that the company utilizes a leveraged capital structure relative to its equity base, which amplifies risk but may also enhance returns if operational performance improves. The current ratio is recorded at 7.88, a figure that suggests strong short-term liquidity as the company holds significantly more current assets relative to its current liabilities, providing a comfortable buffer against immediate financial obligations. Furthermore, the return on equity is -17.6% and the return on assets is -6.2%, metrics that reveal that management has not yet been effective in generating positive returns on the capital invested by shareholders or utilized in assets, reflecting the current stage of business development where reinvestment costs outweigh financial gains.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A and the forward P/E is also N/A, meaning that traditional earnings-based valuation metrics are not applicable due to the absence of positive net income, and consequently, no comparison can be made regarding expected earnings trajectories based on these specific ratios. The price-to-book ratio is N/A, preventing a direct assessment of whether the market is pricing the company at a premium or discount relative to its net asset value, while the price-to-sales ratio and EV/EBITDA are also listed as N/A, requiring reliance on alternative metrics or qualitative factors for valuation analysis. In terms of trading range, the stock has experienced significant volatility within the past year, reaching a 52-week high of $10.28 and a 52-week low of $3.00, placing the current trading price somewhere within this wide band and reflecting the speculative nature of investing in a company with no earnings history. The beta value is 0.37, which indicates that the stock's price volatility is significantly lower than that of the broader market, suggesting a defensive characteristic or lower sensitivity to general market movements despite the lack of earnings. This low beta contrasts with the wide price range, suggesting that while the stock price can fluctuate substantially between $3.00 and $10.28, the overall correlation with market indices remains muted, potentially due to the specific niche of the business or limited trading volume.
Growth & Income
Pulsenmore Ltd. has achieved a revenue growth rate of 578.3% year-over-year, whereas the earnings growth rate is N/A due to the company's current unprofitable status, indicating that revenue expansion is occurring without a corresponding immediate increase in net income. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that the firm retains all of its earnings and cash flow to reinvest into research, development, and market expansion rather than distributing income to shareholders. This strategy of retaining earnings is consistent with the profile of a pre-profitability growth company that seeks to fund its own operations and reduce the need for external financing. Overall, the company presents a high-growth profile driven by substantial revenue expansion but lacks an income profile, as it relies entirely on capital appreciation potential rather than dividend distributions to provide returns to its investors.